Novo Nordisk's top-line phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
News|Videos|August 21, 2017
What Should Pharmacists Advise Diabetes Patients About Lifestyle Modifications?
In this clip, Brooke Hudspeth, PharmD, CDE, of the Kroger Co., explains how pharmacists can play a role in reinforcing the importance of lifestyle modifications for the prevention and management of type 2 diabetes.
Advertisement
In this clip, Brooke Hudspeth, PharmD, CDE, of the Kroger Co., explains how pharmacists can play a role in reinforcing the importance of lifestyle modifications for the prevention and management of type 2 diabetes.
Advertisement
Related to this article
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
3
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5